• DexCom recently reported preliminary, unaudited fourth-quarter 2025 revenue of about US$1.26 billion, up 13% year over year, and full-year 2025 revenue of roughly US$4.66 billion, with guidance calling for 2026 revenue between US$5.16 billion and US$5.25 billion.
• The company tied this outlook to growing sensor volumes, the rollout of its new G7 15 Day system and Stelo product, and further international expansion, underscoring how product innovation and broader CGM adoption are shaping its growth profile.
• We’ll now examine how DexCom’s stronger-than-expected preliminary 2025 revenue and upbeat 2026 outlook may influence its longer-term investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 38 companies in the world exploring or producing it. Find the list for free.

DexCom Investment Narrative Recap

To own DexCom, you need to believe continuous glucose monitoring will keep gaining traction, and that DexCom can defend its position through innovation like G7 15 Day and Stelo. The stronger preliminary 2025 revenue and 2026 guidance support the near term growth catalyst of sensor volume expansion, but they do not remove the key risk of intensifying competition, particularly as rivals push aggressively into insulin intensive and broader diabetes segments.

The most relevant recent development here is DexCom’s preliminary, unaudited 2025 results and 2026 revenue outlook of US$5.16 billion to US$5.25 billion, tied directly to sensor volume growth and international expansion. For investors focused on catalysts, this guidance links the commercial rollouts of G7 15 Day and Stelo to DexCom’s revenue ambitions, while also setting a clearer reference point for judging how competitive pressures and reimbursement changes might affect future performance.

However, against this encouraging top line outlook, investors should be aware that competition in DexCom’s core insulin intensive segment could...

DexCom's narrative projects $6.5 billion revenue and $1.4 billion earnings by 2028.

Uncover how DexCom's forecasts yield a $85.27 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community span roughly US$53 to US$97 per share, underlining how far apart individual views can sit. Some of these investors will be weighing DexCom’s upgraded 2026 revenue outlook against the risk that stronger CGM rivals may pressure pricing and share over time, so it can be useful to compare several of these perspectives side by side.

Explore 6 other fair value estimates on DexCom - why the stock might be worth 23% less than the current price!

Build Your Own DexCom Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your DexCom research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.

No Opportunity In DexCom?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.